3月26日,巨子生物(02367)发布2024年全年业绩公告,延续重组胶原蛋白赛道的高增长传奇。财报显示,巨子生物2024年营收55.39亿元、净利润20.62亿元,增长势头强劲;薇娅夫妇持股增添资本光环。但类传销旧疾、原料成本下降、直销依赖与研发短板等隐忧不少,威胁其“重组胶原第一股”的造富神话。高增长高毛利背后的盈利密码报告期内,巨子生物实现营收55.39亿元,同比增长57.2%;净利润...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.